+152.1%
INTC vs MRNA
+521.0%
-368.9%
-70.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.6% | +0.7% | -6.3% | -5.6% |
| 7D | +9.4% | -8.2% | +17.7% | +9.9% |
| 30D | +2.7% | +125.6% | -122.9% | -7.9% |
| 3M | -6.3% | +197.1% | -203.3% | -19.1% |
| 6M | +114.5% | +148.5% | -34.0% | +88.7% |
| YTD | +171.9% | +363.3% | -191.4% | +123.3% |
| 1Y | +305.0% | +462.0% | -157.0% | +224.6% |
| 3Y | +168.3% | +26.9% | +141.4% | +138.2% |
| 5Y | +102.3% | -69.6% | +171.9% | +86.2% |
| All | +152.1% | +521.0% | -368.9% | +116.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling